| Bayer to develop new manufacturing facility | Posted on 01/10/2008 in Pharmaceutical Company Restructures Bayer Innovation has announced a collaboration agreement with Kentucky Bioprocessing to develop a new facility to produce biopharmaceuticals.
At the site, plant made pharmaceutical proteins and other products will be produced in tobacco plants using the proprietary magnIcon technology from Bayer.
Under the terms of the deal, Kentucky Bioprocessign will adapt its existing current site by installing an automated system for the high throughput transfection of tobacco host plants.
Bayer said this deal makes Kentucky Bioprocessing its preferred production partner for the application of its technology for fast high-yield production of proteins in tobacco plants.
The firm added it has a number of product development projects based on the magnIcon platform, such as a vaccine for non-Hodgkin lymphoma.
Dr Detlef Wollweber, general manager of Bayer Innovation, said: "To accelerate these applications of this technology, we decided to team up with an experienced external manufacturer."
He added with its highly-qualified staff and superior facilities, Kentucky Bioprocessing is the best choice for the company.
In June 2008, Bayer announced the development of a production process to manufacture drugs in tobacco plants with its subsidiary Icon Genetics and predicted the start of clinical trials in 2009.Other news stories from 01/10/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
